Business
Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding
Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding Canada...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VICTORIA, BC\n \n ,\n \n Nov. 4, 2021\n \n /CNW/ - Eupraxia Pharmaceuticals Inc.\n \n \n (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced it is receiving advisory services and funding up to\n \n $700,000\n \n from the\n \n National Research Council\n \n of Canada Industrial Research Assistance Program (\"NRC IRAP\") to support a research and development project to further develop the Company's polymer-based proprietary drug delivery technology.\n \n \n \n \n \n \n \n \n \n \"We are pleased to receive this support from NRC IRAP that we will use to support the development of our underlying platform technology and the identification of additional therapeutic targets for our pipeline of locally delivered, extended-release drug candidates,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia.\n \n \n \n About EP-104IAR\n \n \n \n Eupraxia's lead product candidate, EP-104IAR, is designed to meet the significant unmet medical need and market demand for long-lasting pain relief for knee OA. The U.S. Centers for Disease Control and Prevention estimates that knee OA affects more than 30 million people in the U.S. alone. This includes 14 million that suffer with knee pain or some form of disability. Knee OA is also associated with depression and loss of sleep, which can greatly affect quality of life.\n \n \n With EP-104IAR, Eupraxia hopes to change the way knee OA pain is treated. Current therapies are challenged by poor safety, inadequate efficacy and/or limited duration of activity. Corticosteroids are one of only two drug classes strongly recommended by the American College of Rheumatology and the Arthritis Foundation for the treatment of knee OA pain. Currently approved corticosteroids are very effective at reducing pain for a short duration but can expose the body to unwanted local and ...